뒤로
Boundless Bio Inc(BOLD) 가격
BOLD 주가 차트
BOLD 수입
Boundless Bio Inc
$1.14
-1.29%
$-0.01
종가: Feb 09, 16:00:00 GMT-5
$1.14
-0.41%
$0
애프터마켓: Feb 09, 20:03:22 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-05
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
BOLD의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Boundless Bio Inc BOLD의 지난 분기 매출 실적은 어땠나요?
Boundless Bio Inc의 매출 추정치는 얼마인가요?
Boundless Bio Inc의 수익 품질 점수는 얼마인가요?
Boundless Bio Inc는 언제 수익을 보고하나요?
Boundless Bio Inc의 예상 수익은 얼마인가요?
Boundless Bio Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.16
시가
$1.18
일일 범위
$1.13 - $1.19
52주 범위
$0.961 - $2.48
거래량
105.2K
평균 거래량
168.8K
EPS(TTM)
-16.57
배당수익률
--
시가총액
$25.5M
BOLD란 무엇인가요?
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.